Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.63 |
| ▸ | PPARG | P37231 | 3/20 | 0.51 |
| ▸ | PPARA | Q07869 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11719466 | 1.00 | LDHA (0.63) | LDHAPPARGPPARAALDH1A1SMN1; SMN2 | |
| SCHEMBL21057113 | 0.85 | LDHA (0.59) | LDHAPPARGPPARAALDH1A1SMN1; SMN2 | |
| SCHEMBL21057110 | 0.85 | LDHA (0.59) | LDHAPPARGPPARAALDH1A1SMN1; SMN2 | |
| SCHEMBL17904962 | 0.84 | PPARG (0.62) | PPARGPPARAALDH1A1LMNACYP1A2 | |
| SCHEMBL8846721 | 0.84 | PPARG (0.62) | PPARGPPARAALDH1A1LMNACYP1A2 | |
| SCHEMBL8935857 | 0.84 | PPARG (0.62) | PPARGPPARAALDH1A1LMNACYP1A2 | |
| SCHEMBL22804897 | 0.83 | LDHA (0.52) | LDHAPPARGPPARAALDH1A1SMN1; SMN2 | |
| SCHEMBL22804899 | 0.83 | LDHA (0.52) | LDHAPPARGPPARAALDH1A1SMN1; SMN2 | |
| SCHEMBL11519130 | 0.82 | PPARG (0.53) | LDHAPPARGPPARAALDH1A1TDP1 | |
| SCHEMBL11708010 | 0.82 | PPARG (0.53) | LDHAPPARGPPARAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007639-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2026-01-08 | — | — | US | disclosed |
| US-12440477-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2025-10-14 | — | — | US | disclosed |
| EP-3986873-B9 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2024-05-29 | — | — | EP | disclosed |
| EP-3986873-B1 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2023-11-15 | — | — | EP | disclosed |
| EP-3986873-B1 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2023-11-15 | — | — | EP | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11591284-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-02-28 | — | — | US | disclosed |
| US-20220274938-A1 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2022-09-01 | — | — | US | disclosed |
| EP-3986873-A1 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020254558-A1 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2020-12-24 | — | — | WO | disclosed |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS | 2019-06-20 | — | — | US | disclosed |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA APS (DK) | 2018-04-12 | — | — | US | disclosed |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA APS (DK) | 2018-04-12 | — | — | US | disclosed |
| US-6300352-B1 | FOR THERAPY OF ASTHMA | ASTRAZENECA AB (SE) | 2001-10-09 | — | — | US | disclosed |
| EP-0971892-A1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Astra Pharmaceuticals Limited (GB) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998042670-A1 | NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | LDHA 2645/4885PPARG 3332/4885PPARA 3247/4885 |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | LDHA 2645/4885PPARG 3332/4885PPARA 3247/4885 |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | CPT1B, CLCN2, CACNB1 | LDHA 1122/4885PPARG 997/4885PPARA 821/4885 |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | CPT1B, CLCN2, TNNC1 | LDHA 933/4885PPARG 2105/4885PPARA 2774/4885 |
| US-20220274938-A1 | 5-[(1S)-1-(4-BROMOPHENOXY)ETHYL]-2H-TETRAZOLE DERIVATIVES AND RELATED COMPOUNDS AS CLC-1 ION CHANNEL INHIBITORS FOR TREATING NEUROMUSCULAR DISORDERS | RYR1, CACNB1, CACNA1D | LDHA 1541/4885PPARG 3385/4885PPARA 4010/4885 |
| US-12440477-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | LDHA 2645/4885PPARG 3332/4885PPARA 3247/4885 |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | LDHA 2645/4885PPARG 3332/4885PPARA 3247/4885 |
| US-11591284-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, CACNA1S | LDHA 2342/4885PPARG 1323/4885PPARA 827/4885 |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | LDHA 2645/4885PPARG 3332/4885PPARA 3247/4885 |
| US-20260007639-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | RYR1, CLIC1, RYR2 | LDHA 2314/4885PPARG 2878/4885PPARA 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.